Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease
Descripción general
Resumen del artículo
This review summarizes the evidence supporting the use of multiple medications (combination therapy) to treat chronic kidney disease, particularly in people with diabetes. Recent advances have introduced several drug classes with complementary mechanisms for protecting the kidneys and cardiovascular system. These medications include SGLT2 inhibitors, GLP-1 receptor agonists, and the non-steroidal mineralocorticoid receptor antagonist finerenone.
Explícamelo como si tuviera cinco años
This review discusses using multiple medications together to treat chronic kidney disease, especially in people with diabetes. Combining drugs might better target the disease's different causes.
Posibles conflictos de intereses
The supplement containing this review was financially supported by Bayer AG, a pharmaceutical company that manufactures some of the medications discussed. Several authors also reported receiving research grants, consulting fees, and other support from various pharmaceutical companies.
Limitaciones identificadas
Explicación de la calificación
This review provides a thorough overview of the rationale and evidence for using combination therapy in chronic kidney disease. The authors discuss the relevant pathophysiology, summarize key clinical trials, and address practical implications. Although the narrative review format carries an inherent risk of bias, the authors transparently disclose potential conflicts of interest related to industry funding and support.
Conviene saber
Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.
Explorar Pro →